newsfilter
← Latest News
GlobeNewswire·

Satsuma Pharmaceuticals to Participate in the Virtual SVB Securities Global Biopharma Conference

SOUTH SAN FRANCISCO, Calif., Feb. 02, 2023 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (NASDAQ:STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder), a novel